The 15-lipoxygenase-modified high density lipoproteins 3 fail to inhibit the TNF-α-induced inflammatory response in human endothelial cells

Journal of Immunology

Volumn 181, Issue 4, 2008, Pages 2821-2830

  Pirillo, Angela ^a   Uboldi, Patrizia ^a   Bolego, Chiara ^b   Kuhn, Hartmut ^c   Catapano, Alberico Luigi ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN 3; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN C JUN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; ALOX15 PROTEIN, HUMAN; AUTACOID; CELL ADHESION MOLECULE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ADHESION; CELL STRAIN U937; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INFLAMMATION; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; BIOSYNTHESIS; CELL CULTURE; CELL LINE; DOSE RESPONSE; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; MICROCIRCULATION; PATHOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ARACHIDONATE 15-LIPOXYGENASE; CELL ADHESION MOLECULES; CELL LINE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION MEDIATORS; LIPOPROTEINS, HDL3; MICROCIRCULATION; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

EID: 53149097776     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.4.2821     Document Type: Article

References (68)

1. Ross, R. 1999. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340: 115-126.
2. Hansson, G. K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352: 1685-1695.
3. Libby, P. 2002. Inflammation in atherosclerosis. Nature 420: 868-874.
4. Deanfield, J. E., J. P. Halcox, and T. J. Rabelink. 2007. Endothelial function and dysfunction: testing and clinical relevance. Circulation 115: 1285-1295.
5. Simionescu, M. 2007. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler. Thromb. Vasc. Biol. 27: 266-274.
6. Blankenberg, S., S. Barbaux, and L. Tiret. 2003. Adhesion molecules and atherosclerosis. Atherosclerosis 170: 191-203.
7. Rao, R. M., L. Yang, G. Garcia-Cardena, and F. W. Luscinskas. 2007. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ. Res. 101: 234-247.
8. Charo, I. F., and M. B. Taubman. 2004. Chemokines in the pathogenesis of vascular disease. Circ. Res. 95: 858-866.
9. Osterud, B., and E. Bjorklid. 2003. Role of monocytes in atherogenesis. Physiol. Rev. 83: 1069-1112.
10. Gordon, D. J., and B. M. Rifkind. 1989. High-density lipoprotein: the clinical implications of recent studies. N. Engl. J. Med. 321: 1311-1316.
11. Assmann, G., and H. Schulte. 1992. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience): prospective cardiovascular Munster study. Am. J. Cardiol. 70: 733-737.
12. Assmann, G., H. Schulte, A. von Eckardstein, and Y. Huang. 1996. Highdensity lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124: S11-S20.
13. Ansell, B. J., M. Navab, S. Hama, N. Kamranpour, G. Fonarow, G. Hough, S. Rahmani, R. Mottahedeh, R. Dave, S. T. Reddy, and A. M. Fogelman. 2003. Inflammatory/Antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108: 2751-2756.
14. Castelli, W. P., R. J. Garrison, P. W. Wilson, R. D. Abbott, S. Kalousdian, and W. B. Kannel. 1986. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. J. Am. Med. Assoc. 256: 2835-2838.
15. Assmann, G., and A. M. Gotto, Jr. 2004. HDL cholesterol and protective factors in atherosclerosis. Circulation 109: III8-III14.
16. Nofer, J. R., B. Kehrel, M. Fobker, B. Levkau, G. Assmann, and A. von Eckardstein. 2002. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161: 1-16.
17. Assmann, G., and J. R. Nofer. 2003. Atheroprotective effects of high-density lipoproteins. Annu. Rev. Med. 54: 321-341.
18. Yuhanna, I. S., Y. Zhu, B. E. Cox, L. D. Hahner, S. Osborne-Lawrence, P. Lu, Y. L. Marcel, R. G. Anderson, M. E. Mendelsohn, H. H. Hobbs, and P. W. Shaul. 2001. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7: 853-857.
19. Nofer, J. R., S. Geigenmuller, C. Gopfert, G. Assmann, E. Buddecke, and A. Schmidt. 2003. High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells. Biochem. Biophys. Res. Commun. 310: 98-103.
20. Park, S. H., J. H. Park, J. S. Kang, and Y. H. Kang. 2003. Involvement of transcription factors in plasma HDL protection against TNF-α-induced vascular cell adhesion molecule-1 expression. Int. J. Biochem. Cell Biol. 35: 168-182.
21. Cockerill, G. W., K. A. Rye, J. R. Gamble, M. A. Vadas, and P. J. Barter. 1995. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15: 1987-1994.
22. Ansell, B. J., G. C. Fonarow, and A. M. Fogelman. 2007. The paradox of dysfunctional high-density lipoprotein. Curr. Opin. Lipidol. 18: 427-434.
23. Bergt, C., S. Pennathur, X. Fu, J. Byun, K. O'Brien, T. O. McDonald, P. Singh, G. M. Anantharamaiah, A. Chait, J. Brunzell, et al. 2004. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. USA 101: 13032-13037.
24. Suc, I., S. Brunet, G. Mitchell, G. E. Rivard, and E. Levy. 2003. Oxidative tyrosylation of high density lipoproteins impairs cholesterol efflux from mouse J774 macrophages: role of scavenger receptors, classes A and B. J. Cell Sci. 116: 89-99.
25. Marsche, G., A. Hammer, O. Oskolkova, K. F. Kozarsky, W. Sattler, and E. Malle. 2002. Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoproteindependent selective lipid uptake and reverse cholesterol transport. J. Biol. Chem. 277: 32172-32179.
26. Pirillo, A., P. Uboldi, H. Kuhn, and A. L. Catapano. 2006. 15-Lipoxygenasemediated modification of high-density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages. Biochim. Biophys. Acta 1761: 292-300.
27. Conrad, D. J., H. Kuhn, M. Mulkins, E. Highland, and E. Sigal. 1992. Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc. Natl. Acad. Sci. USA 89: 217-221.
28. Heydeck, D., L. Thomas, K. Schnurr, F. Trebus, W. E. Thierfelder, J. N. Ihle, and H. Kuhn. 1998. Interleukin-4 and -13 induce up-regulation of the murine macrophage 12/15-lipoxygenase activity: evidence for the involvement of transcription factor STAT6. Blood 92: 2503-2510.
29. Yla-Herttuala, S., M. E. Rosenfeld, S. Parthasarathy, E. Sigal, T. Sarkioja, J. L. Witztum, and D. Steinberg. 1991. Gene expression in macrophage-rich human atherosclerotic lesions: 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J. Clin. Invest. 87: 1146-1152.
30. Yla-Herttuala, S., M. E. Rosenfeld, S. Parthasarathy, C. K. Glass, E. Sigal, J. L. Witztum, and D. Steinberg. 1990. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc. Natl. Acad. Sci. USA 87: 6959-6963.
31. Folcik, V. A., R. A. Nivar-Aristy, L. P. Krajewski, and M. K. Cathcart. 1995. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J. Clin. Invest. 96: 504-510.
32. Kuhn, H., D. Heydeck, I. Hugou, and C. Gniwotta. 1997. In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J. Clin. Invest. 99: 888-893.
33. Belkner, J., H. Stender, and H. Kuhn. 1998. The rabbit 15-lipoxygenase preferentially oxygenates LDL cholesterol esters, and this reaction does not require vitamin E. J. Biol. Chem. 273: 23225-23232.
34. Jaffe, E. A., R. L. Nachman, C. G. Becker, and C. R. Minick. 1973. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J. Clin. Invest. 52: 2745-2756.
35. Ades, E. W., F. J. Candal, R. A. Swerlick, V. G. George, S. Summers, D. C. Bosse, and T. J. Lawley. 1992. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol. 99: 683-690.
36. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
37. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275.
38. Norata, G. D., G. Tibolla, P. M. Seccomandi, A. Poletti, and A. L. Catapano. 2006. Dihydrotestosterone decreases tumor necrosis factor-α and lipopolysaccharide-induced inflammatory response in human endothelial cells. J. Clin. Endocrinol. Metab. 91: 546-554.
39. Calabresi, L., G. Franceschini, C. R. Sirtori, A. De Palma, M. Saresella, P. Ferrante, and D. Taramelli. 1997. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem. Biophys. Res. Commun. 238: 61-65.
40. Weber, C., W. Erl, A. Pietsch, M. Strobel, H. W. Ziegler-Heitbrock, and P. C. Weber. 1994. Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-κB mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. Arterioscler. Thromb. 14: 1665-1673.
41. Rahman, A., J. Kefer, M. Bando, W. D. Niles, and A. B. Malik. 1998. E-selectin expression in human endothelial cells by TNF-α-induced oxidant generation and NF-κB activation. Am. J. Physiol. 275: L533-L544.
42. Collins, T., M. A. Read, A. S. Neish, M. Z. Whitley, D. Thanos, and T. Maniatis. 1995. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers. FASEB J. 9: 899-909.
43. O'Connell, B. J., and J. Genest, Jr. 2001. High-density lipoproteins and endothelial function. Circulation 104: 1978-1983.
44. Barter, P., J. Kastelein, A. Nunn, and R. Hobbs. 2003. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 168: 195-211.
45. Barter, P. J., S. Nicholls, K. A. Rye, G. M. Anantharamaiah, M. Navab, and A. M. Fogelman. 2004. Antiinflammatory properties of HDL. Circ. Res. 95: 764-772.
46. Navab, M., G. M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, B. J. Ansell, and A. M. Fogelman. 2006. Mechanisms of disease: proatherogenic HDL: an evolving field. Nat. Clin. Pract. Endocrinol. Metab. 2: 504-511.
47. Fogelman, A. M. 2004. When good cholesterol goes bad. Nat. Med. 10: 902-903.
48. Kontush, A., E. C. de Faria, S. Chantepie, and M. J. Chapman. 2005. A normotriglyceridemic, low HDL-cholesterol phenotype is characterized by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 182: 277-285.
49. Nobecourt, E., S. Jacqueminet, B. Hansel, S. Chantepie, A. Grimaldi, M. J. Chapman, and A. Kontush. 2005. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycemia. Diabetologia 48: 529-538.
50. Khovidhunkit, W., M. S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2004. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45: 1169-1196.
51. Esteve, E., W. Ricart, and J. M. Fernandez-Real. 2005. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin. Nutr. 24: 16-31.
52. Kontush, A., and M. J. Chapman. 2006. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58: 342-374.
53. Hansel, B., P. Giral, E. Nobecourt, S. Chantepie, E. Bruckert, M. J. Chapman, and A. Kontush. 2004. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab. 89: 4963-4971.
54. Ottestad, I. O., B. Halvorsen, T. R. Balstad, K. Otterdal, G. I. Borge, F. Brosstad, A. M. Myhre, L. Ose, M. S. Nenseter, and K. B. Holven. 2006. Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux. J. Nutr. 136: 877-881.
55. Van Lenten, B. J., S. Y. Hama, F. C. de Beer, D. M. Stafforini, T. M. McIntyre, S. M. Prescott, B. N. La Du, A. M. Fogelman, and M. Navab. 1995. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96: 2758-2767.
56. Van Lenten, B. J., A. C. Wagner, D. P. Nayak, S. Hama, M. Navab, and A. M. Fogelman. 2001. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 103: 2283-2288.
57. Hedrick, C. C., S. R. Thorpe, M. X. Fu, C. M. Harper, J. Yoo, S. M. Kim, H. Wong, and A. L. Peters. 2000. Glycation impairs high-density lipoprotein function. Diabetologia 43: 312-320.
58. Ferretti, G., T. Bacchetti, C. Marchionni, L. Caldarelli, and G. Curatola. 2001. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol. 38: 163-169.
59. Marsche, G., R. Heller, G. Fauler, A. Kovacevic, A. Nuszkowski, W. Graier, W. Sattler, and E. Malle. 2004. 2-chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler. Thromb. Vasc. Biol. 24: 2302-2306.
60. Lum, H., and K. A. Roebuck. 2001. Oxidant stress and endothelial cell dysfunction. Am. J. Physiol. 280: C719-C741.
61. Xia, P., M. A. Vadas, K. A. Rye, P. J. Barter, and J. R. Gamble. 1999. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway: a possible mechanism for protection against atherosclerosis by HDL. J. Biol. Chem. 274: 33143-33147.
62. Schmidt, A., S. Geigenmuller, W. Volker, and E. Buddecke. 2006. The antiatherogenic and antiinflammatory effect of HDL-associated lysosphingolipids operates via Akt→NF-κB signalling pathways in human vascular endothelial cells. Basic Res. Cardiol. 101: 109-116.
63. Voraberger, G., R. Schafer, and C. Stratowa. 1991. Cloning of the human gene for intercellular adhesion molecule 1 and analysis of its 5′-regulatory region: induction by cytokines and phorbol ester. J. Immunol. 147: 2777-2786.
64. Argraves, K. M., and W. S. Argraves. 2007. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J. Lipid Res. 48: 2325-2333.
65. Kimura, T., H. Tomura, C. Mogi, A. Kuwabara, A. Damirin, T. Ishizuka, A. Sekiguchi, M. Ishiwara, D. S. Im, K. Sato, et al. 2006. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem. 281: 37457-37467.
66. Kimura, T., K. Sato, A. Kuwabara, H. Tomura, M. Ishiwara, I. Kobayashi, M. Ui, and F. Okajima. 2001. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J. Biol. Chem. 276: 31780-31785.
67. +-activated potassium channels is involved in lysophosphatidylcholine-induced monocyte adhesion to endothelial cells. Atherosclerosis 190: 100-105.
68. Rizza, C., N. Leitinger, J. Yue, D. J. Fischer, D. A. Wang, P. T. Shih, H. Lee, G. Tigyi, and J. A. Berliner. 1999. Lysophosphatidic acid as a regulator of endothelial/ leukocyte interaction. Lab. Invest. 79: 1227-1235.